Latvia vs Paraguay: Access to anti-retroviral drugs, female
Latvia
54.0%
in 2024
Paraguay
55.0%
in 2024
Latvia rank
114th
Paraguay rank
111th
Access to anti-retroviral drugs, female over time
- Latvia
- Paraguay
How they compare
Paraguay currently reports 55.0% against 54.0% in Latvia, a difference of 1.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Latvia ahead.
Latvia ranks 114th and Paraguay ranks 111th of 141 countries.
Paraguay has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Latvia | Paraguay | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.5% | 6.1% | 3.6% | Paraguay |
| 2010s | 20.4% | 37.9% | 17.5% | Paraguay |
| 2020s | 51.2% | 52.4% | 1.2% | Paraguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Latvia or Paraguay?
- Paraguay, at 55.0% against 54.0% in Latvia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Latvia and Paraguay?
- 1.0%, with Paraguay ahead.
- How many years of comparable data are there for Latvia and Paraguay?
- 25 years are reported by both, from 2000 to 2024.
- How do Latvia and Paraguay rank globally for access to anti-retroviral drugs, female?
- Latvia ranks 114th and Paraguay ranks 111th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.